Zydus Cadila has received final approval from the USFDA to market Potassium Chloride ExtendedRelease Tablets (US RLD: K-Dur Extended-Release Tablets) in the strengths of 10 mEq (750 mg) and 20 mEq (1500 mg).
The medication is a mineral supplement used to treat or prevent low amounts of potassium in the blood and will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.
The group now has 301 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.394.2 as compared to the previous close of Rs. 388.45. The total number of shares traded during the day was 324448 in over 6535 trades.
The stock hit an intraday high of Rs. 396.4 and intraday low of 384.6. The net turnover during the day was Rs. 126837544.